MX2021001870A - Metodo para tratar cancer pancreatico. - Google Patents

Metodo para tratar cancer pancreatico.

Info

Publication number
MX2021001870A
MX2021001870A MX2021001870A MX2021001870A MX2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A
Authority
MX
Mexico
Prior art keywords
subject
treating pancreatic
pancreatic cancer
administering
effective amount
Prior art date
Application number
MX2021001870A
Other languages
English (en)
Inventor
Marla L Weetall
Liangxian Cao
Thomas W Davis
Melissa L Dumble
Jaime A Eberle-Singh
Kenneth P Olive
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021001870A publication Critical patent/MX2021001870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente solicitud se describe un método para tratar cáncer pancreático en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto inhibidor de la polimerización de tubulina. De manera más particular, en la presente solicitud se describe un método para tratar adenocarcinoma ductal pancreático en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto inhibidor de la polimerización de tubulina de tipo pirimidina inversa sustituida solo o en combinación con otros agentes quimioterapéuticos.
MX2021001870A 2018-08-17 2019-08-17 Metodo para tratar cancer pancreatico. MX2021001870A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719526P 2018-08-17 2018-08-17
PCT/US2019/046972 WO2020055544A2 (en) 2018-08-17 2019-08-17 Method for treating pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2021001870A true MX2021001870A (es) 2021-07-15

Family

ID=69778374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001870A MX2021001870A (es) 2018-08-17 2019-08-17 Metodo para tratar cancer pancreatico.

Country Status (11)

Country Link
US (1) US20210236492A1 (es)
EP (1) EP3836932A2 (es)
JP (1) JP2021535198A (es)
CN (1) CN113164479A (es)
AU (1) AU2019340402A1 (es)
BR (1) BR112021002630A2 (es)
CA (1) CA3109386A1 (es)
IL (1) IL280800A (es)
MX (1) MX2021001870A (es)
TW (1) TW202021961A (es)
WO (1) WO2020055544A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710670A (zh) * 2019-02-28 2021-11-26 Ptc医疗公司 治疗多发性骨髓瘤的方法
EP3947379A4 (en) * 2019-03-27 2022-12-21 PTC Therapeutics, Inc. COMBINATIONS FOR USE IN A METHOD OF TREATMENT OF SARCOMA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6412503B2 (ja) 2012-11-21 2018-10-24 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors

Also Published As

Publication number Publication date
CN113164479A (zh) 2021-07-23
JP2021535198A (ja) 2021-12-16
AU2019340402A2 (en) 2021-04-01
AU2019340402A1 (en) 2021-03-25
BR112021002630A2 (pt) 2021-05-11
WO2020055544A2 (en) 2020-03-19
US20210236492A1 (en) 2021-08-05
CA3109386A1 (en) 2020-03-19
TW202021961A (zh) 2020-06-16
EP3836932A2 (en) 2021-06-23
IL280800A (en) 2021-04-29
WO2020055544A3 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
ZA201906001B (en) Combination therapy for the treatment or prevention of tumours
EP4302835A3 (en) Methods of treating ovarian cancer
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
PH12014502048A1 (en) Treatment of cancer with tor kinase inhibitors
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EA201792346A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc)
MX2022001004A (es) Inhibidores de enzimas.
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
WO2020115491A3 (en) Immune checkpoint inhibitor in combination with sonodynamic therapy
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
MX2021001870A (es) Metodo para tratar cancer pancreatico.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2020010721A (es) Moduladores de la expresion de ezh2.
MX2020007342A (es) Compuestos de sililetinilo hetarilo como inhibidores de la nitrificacion.
MX2022003686A (es) Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial.